PAG-led API Platform concludes acquisition of controlling stake in Optimus Group
The deal follows the acquisition of Anjan Drugs in 2020 by the consortium, which aims to develop a best-in-class center for the development and production of bulk drug ingredients.
Mumbai: PAG, a leading global investment firm, announced today that its private equity strategy, along with consortium partners CX Partners and Samara Capital, has completed the acquisition of a controlling stake in the Optimus Group, a Hyderabad, India-based pharmaceutical firm, through the API platform, Sekhmet Pharmaventures.
Founded in 2004, Optimus is a vertically integrated manufacturer of pharmaceutical products including advanced intermediates, active pharmaceutical ingredients (APIs) and finished drugs. It currently exports more than 100 products to 40 countries.
Read also: Optimus Pharma seeks DCGI nod to produce generic version of Molnupiravir
Nikhil Srivastava, Partner and Managing Director, Head of India Private Equity for PAG, commented: "We are excited to partner with Srini and the team at Optimus as it embarks on a new phase of growth. We look forward to supporting Optimus to continue to invest in its R&D, manufacturing capabilities and intellectual property management, and serve the health needs of people in India and across the globe."
Dr. D. Srinivas Reddy, the founder of Optimus, said: "Sekhmet's investment significantly boosts our product development capabilities, and further enables us to achieve our ambition of becoming a leading global API producer. We look forward to working with PAG consortium to build our portfolio to deliver high quality, affordable health products, and offer our customers industry-leading products across a wide spectrum of medical needs."
Read also: PAG, partners to acquire controlling stake in Optimus Drugs for Rs 2,000 crore
The deal follows the acquisition of Anjan Drugs in 2020 by the consortium, which aims to develop a best-in-class center for the development and production of bulk drug ingredients.
PAG views India as a particularly attractive market. With this transaction, PAG has invested more than USD700 million in private equity in India over the last two years across multiple sectors.
Read also: CCI approves acquisition of majority shareholding in Optimus Drugs by Sekhmet Pharmaventures
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.